Credit Strategies Fund Metrics · enters a phase of heavy M&A activity. Irish drug maker Actavis...

5
MONTHLY NEWSLETTER Investment Objective Credit Strategies Fund Metrics Fund Performance (Class A, net of all fees and expenses) 1 Year Jan Feb Mar Apr May Jun July Aug Sept Oct Nov Dec YTD 2015 0.52% 1.54% 0.15% 2.22% 2014 0.44% 1.32% 0.87% 0.85% 0.48% 0.41% 0.01% 0.09% -0.28% 0.33% 0.10% -0.27% 4.44% 2013 1.12% 0.42% 0.43% 0.52% 0.54% -2.52% 0.53% 0.21% 0.00% 1.18% 0.92% 0.94% 4.33% 2012 0.53% 0.36% -0.43% 1.33% 1.61% 0.89% 1.59% 1.06% 0.54% 1.03% 8.83% Growth of $1000 Since Inception - (Mar 1, 2012 - Mar 31,2015) Ratings reflect portfolio holdings as of Mar 31, 201521.21% 15.88% 8.58% Lawrence Park Capital Partners Ltd. 2 Berkeley Street, Suite 304, Toronto, Ontario, Canada M5A 4J5 WWW.LPCAPITALPARTNERS.COM XCB:XCB CN EQUITY │BGCI: Barclays Global Corporate Index Annualized Return Volatility 4 Sharpe Ratio 4 2.22% 3.23% 2.54% 6.44% 4.90% 2.71% 0.82 Metric LPCSF XCB 2 BGCI 3 YTD Return Total Return since Inception 1, 2 Risk and Return Metrics March, 2015 The Fund seeks to deliver 6-10% annual returns with volatility at or below traditional fixed income. The manager invests primarily in domestic and global corporate bonds, and protects against interest rate volatility. The Fund is actively managed across a number of relative value and trading strategies, and is based on the founding principles of delivering capital preservation, low volatility and consistent returns. 0.34% 3.24% 2.07% 2.08 1.19 CREDIT Canada 47% Europe 17% United States 34% Asset Holdings by Region 5 0% 10% 20% 30% 40% 50% 60% AAA AA A BBB BB B STRATEGIES FUND 980 1,000 1,020 1,040 1,060 1,080 1,100 1,120 1,140 1,160 1,180 1,200 1,220 1,240 GROWTH OF $1,000 SINCE INCEPTION: Mar 1, 2012 - Mar 31, 2015 inclusive LPCSF XCB BGCI Corporate Bond Index Corporate Spread Index 1,212 1,159 1,086 2 3 1

Transcript of Credit Strategies Fund Metrics · enters a phase of heavy M&A activity. Irish drug maker Actavis...

Page 1: Credit Strategies Fund Metrics · enters a phase of heavy M&A activity. Irish drug maker Actavis raised an impressive US$20 billion to fund its takeover of Allergen, while rival Valeant

MONTHLY NEWSLETTER

Investment Objective

Credit Strategies Fund Metrics Fund Performance (Class A, net of all fees and expenses)

1

Year Jan Feb Mar Apr May Jun July Aug Sept Oct Nov Dec YTD

2015 0.52% 1.54% 0.15% 2.22%

2014 0.44% 1.32% 0.87% 0.85% 0.48% 0.41% 0.01% 0.09% -0.28% 0.33% 0.10% -0.27% 4.44%

2013 1.12% 0.42% 0.43% 0.52% 0.54% -2.52% 0.53% 0.21% 0.00% 1.18% 0.92% 0.94% 4.33%

2012 0.53% 0.36% -0.43% 1.33% 1.61% 0.89% 1.59% 1.06% 0.54% 1.03% 8.83%

Growth of $1000 Since Inception - (Mar 1, 2012 - Mar 31,2015)

Ratings reflect portfolio holdings as of Mar 31, 2015⁵

21.21% 15.88% 8.58%

Lawrence Park Capital Partners Ltd. 2 Berkeley Street, Suite 304, Toronto, Ontario, Canada M5A 4J5 WWW.LPCAPITALPARTNERS.COM

XCB:XCB CN EQUITY │BGCI: Barclays Global Corporate Index

Annualized

Return

Volatility4

Sharpe Ratio4

2.22% 3.23%

2.54%

6.44% 4.90% 2.71%

0.82

Metric LPCSF XCB2

BGCI3

YTD Return

Total Return

since Inception1, 2

Risk and Return Metrics

March, 2015

The Fund seeks to deliver 6-10% annual returns with volatility at or below traditional fixed income. The manager invests primarily in domestic

and global corporate bonds, and protects against interest rate volatility. The Fund is actively managed across a number of relative value and

trading strategies, and is based on the founding principles of delivering capital preservation, low volatility and consistent returns.

0.34%

3.24% 2.07%

2.08 1.19

CREDIT

Canada 47%

Europe 17%

United States 34%

Asset Holdings by Region5

0% 10% 20% 30% 40% 50% 60%

AA

AA

AA

BB

BB

BB

STRATEGIES FUND

980

1,000

1,020

1,040

1,060

1,080

1,100

1,120

1,140

1,160

1,180

1,200

1,220

1,240

GROWTH OF $1,000 SINCE INCEPTION: Mar 1, 2012 - Mar 31, 2015 inclusive

LPCSF XCB BGCI

Corporate Bond Index

Corporate Spread Index

1,212

1,159

1,086

2 3

1

Page 2: Credit Strategies Fund Metrics · enters a phase of heavy M&A activity. Irish drug maker Actavis raised an impressive US$20 billion to fund its takeover of Allergen, while rival Valeant

Insights from the Trading Desk March 2015

The old adage “in like a lion, out like a lamb” perhaps applied more to corporate bond markets in March than to

seasonal changes in weather. Following a very robust credit rally in February, we began March the same way even as

global equity markets quickly reversed their prior month gains. But by month end it felt like we were limping over the

finish line, a promising start soured by heavy supply and choppy markets. However, in a month where global bond

and equity markets were generally negative we are pleased to have posted a positive return, albeit a modest one.

Signs of an Economic Slowdown

A dominant theme of Q1 economic numbers is that US growth is not accelerating as much as some had predicted

coming into the year. Payroll numbers have remained robust, at least for January and February, but other indicators

such as retail sales and industrial production have thus far surprised to the downside. There have been a lot of

headwinds for the US so far in 2015, including lower oil prices, a stronger dollar, and a severe winter in the northeast.

Of those, the dollar may continue to be a drag on exports, but the other effects should dissipate. It is worth

remembering that 2014 began much the same way, with the US economy contracting in the first quarter before

accelerating in the second half, and it is reasonable to believe that this could be the case again this year.

The Fed: Less Patient but with Lower Dots

The risk rally we enjoyed in February took a breather by mid-March as we awaited the interest rate announcement

from the US Federal Reserve on the 18th. Much was made of the word “patient” from the previous statement – would

it stay or go. Removing “patient” would suggest the first rate hike in almost a decade was distinctly more imminent.

It’s fair to say a lot of anxiety (misplaced in our view) hung on one word.

In the end the Fed did remove the word patient. They also made it clear that the first rate rise would be no earlier

than June, and that the exact timing was highly dependent on inflation and jobs data. But more significantly they

lowered the “dots” – the Fed’s consensus forecast of where the federal funds rate is likely to be over the next 2 years

– by as much as 5/8 of a percent in 2016. This conveyed the message that while rate rises may come sooner, any

subsequent increases may occur at a slower pace than previously anticipated. This went some way to allaying market

fears, and the tone felt more constructive in heading into month end.

North American equity and credit markets are very much back to second-guessing the US Federal Reserve, where

good economic news breeds fear that interest rates will rise faster than anticipated, and vice-versa; good news has

become bad news and bad news good. It’s a fear that will ultimately dissipate (likely later this year when the Fed

actually gets the first hike out of the way and markets can find something else to focus on) but for now we must ride

it out. It also seems clear to us that the Fed is keenly aware of market unease, and is doing everything in its power to

soothe anxiety as they move away from a Zero-Interest-Rate Policy. Whether they are ultimately successful only time

will tell, but thus far we would say they have done a credible job – as supported by US equities persistently remaining

near an all-time high.

Page 3: Credit Strategies Fund Metrics · enters a phase of heavy M&A activity. Irish drug maker Actavis raised an impressive US$20 billion to fund its takeover of Allergen, while rival Valeant

-0.75%

-0.50%

-0.25%

0.00%

0.25%

-3.0%

-2.0%

-1.0%

0.0%

1.0%

01-Mar 08-Mar 15-Mar 22-Mar 29-Mar

US

Liq

uid

Cre

dit

Ind

ex

Re

turn

S&P

Ind

ex

Re

turn

Equity and Credit markets showed little correlation in March

US Stocks (S&P)

US Credit (JULI)

Record Supply Weighs on Markets

If equity markets were focused almost exclusively on central bank activity in March, credit markets had other issues

to deal with. New issue supply, especially in North American markets, was remarkably robust, fuelled by a number of

factors. First, interest rates are low; US 10y notes trading in a 1.75-2.25% range in Q1 which was lower than most

economists had predicted, and Canada even lower following its January rate cut, with 10y bond yields in a 1.30%-

1.60% range.

Second, the basis swap has moved dramatically in favour of

issuing in US dollars. Whereas at the start of the year corporate

issuers could generate significant savings by issuing in Euros to

take advantage of low rates and tight spreads, a 25bp move in

the basis swap has shifted the balance in favour of USD

issuance (multi-national issuers typically use currency swaps to

convert foreign bond issues to their home currency).

And third, we had seen a decent tightening of credit spreads in

February from the January wides. The combination of those three factors meant corporations were flocking to US and

Canadian bond markets to raise money in late February/early March. Barclays’ research suggested a 30% increase in

Investment Grade bond issuance and an over 60% increase in High Yield issuance, compared to the year-ago period.

All this supply was tough for the market to digest, and was a driving

force behind soft credit spreads in March. In fact, credit markets

and equity markets showed even less correlation during the month

than normal, with credit spreads struggling even as equities were

rallying. It was only towards the end of the month as issuance

slowed down that credit markets recovered.

Pharmaceutical giants were active issuers in March as the industry

enters a phase of heavy M&A activity. Irish drug maker Actavis raised an impressive US$20 billion to fund its takeover

of Allergen, while rival Valeant managed a US $8 billion issue for its own purchase of Salix. Meanwhile Exxon Mobil

raised $8 billion, possibly anticipating future acquisitions in the energy sector. Similarly, Europeans were of course

active in the US market, with jumbo deals from UBS, Credit Suisse, and Merck AG. In Canada the banks were active,

with 5 of the Big 6 banks issuing a combined C$7.2 billion. Telus and BCE each brought 30 year issues to finance

recent spectrum acquisition; these deals had been hotly anticipated and performed well in secondary markets.

With April bringing a holiday break (more significant in Europe but still a factor in North America) and the start of

earnings season, we expect reduced issuance activity which should be supportive for credit.

-50

-40

-30

-20

-10

0

10

Apr'14

May'14

Jun'14

Jul'14

Aug'14

Sep'14

Oct'14

Nov'14

Dec'14

Jan'15

Feb'15

Mar'15

A sharp move in the Basis Swap brought more issuance to US bond market

USD-EUR 10y Basis Swap

Source: Bloomberg

Source: JP Morgan /Bloomberg

Page 4: Credit Strategies Fund Metrics · enters a phase of heavy M&A activity. Irish drug maker Actavis raised an impressive US$20 billion to fund its takeover of Allergen, while rival Valeant

European spreads take a breather

The resilience of European credit spreads throughout the second half of 2014 while North American spreads

struggled was a central trading theme for us. The rally in Europe continued in January & February, but March saw a

bounce wider in some sectors. In particular, Yankee markets (European issuance in US dollars) were soft this month,

in part due to the basis spread effects mentioned above. While our European holdings were negative contributors

this month, we believe the technical factors are more balanced at these levels and remain constructive on Europe

from a fundamental point of view.

Energy Spreads remain volatile

Oil and gas spreads continue to be volatile this year as oil hovers in the $45-$50 range. A mid-month dip to new lows

around $43 caused another wave of selling pressure in both stocks and bonds. As we have said in recent

commentary, the longer term outlook for this sector remains in question and we continue to be cautious. There will

undoubtedly be industry consolidation towards stronger players which is supportive for credit markets, but the risk

reward, at least in bonds, remains skewed against taking an aggressive position at this stage.

Trading Themes

Our mix of strategies allowed us to report a modestly positive return in March despite negative months for most

major equity and bond markets. Our short end Carry and Roll strategy was a positive contributor, as was our

Momentum strategy which benefited from busy new issue markets. However Core Holdings underperformed given

broadly wider spreads, particularly with respect to European banks. Our Relative Value bucket had mixed fortunes

this month, with some of our cross-currency strategies giving back February gains, while we managed to unwind

our Amazon-Alibaba curve trade at a profitable level.

Our trading strategy in March was to set the book up for what we see as a reversal of fortune heading into Q2. We

are reducing our holdings in the carry and roll book, as flatter rate curves in Canada and softness in front end spreads

make us less bullish on this strategy. We allowed our overall credit risk profile to increase to take advantage of wider

credit spreads, forecasting improved technicals in April.

Opportunity in Steep Credit Curves

Credit curves have steepened in 2015 driven by a flattening interest rate curves. We see this as an opportunity to

extend our credit exposure, with appropriate interest rate hedges in place. We anticipate that as rate curves stabilize

then credit curves will revert to more normal levels. Buyers of duration (insurance & pensions) are focused on all-in-

yield, and will often hold back on corporate bond buying following a rate rally. But inevitably they eventually return

to the markets to meet their mandate. Our reduction in short end credit and extension to longer dated risk is a key

component of our strategy heading into the second quarter.

As always, we welcome your questions and comments.

The Lawrence Park Team

Page 5: Credit Strategies Fund Metrics · enters a phase of heavy M&A activity. Irish drug maker Actavis raised an impressive US$20 billion to fund its takeover of Allergen, while rival Valeant

Please Read The Following:

1 .

2 .

3 .

4 .

5 .

6 .

7 .

Contact Us2 Berkeley Street, Suite 304 Kathleen Biggs

Toronto, ON M5A 4J5 Director, Business Development

Office: (416) 646-2180 Office: (416) 646-2180 ext. 1029

Fax: (416) 304-9985 [email protected]

www.lpcapitalpartners.com

Lawrence Park Capital Partners Ltd. 2 Berkeley Street, Suite 304, Toronto, Ontario, Canada M5A 4J5 WWW.LPCAPITALPARTNERS.COM

Auditor KPMG

Administrator CI Investments Inc, RBC Investor Services

Legal BLG

High Water Mark Permanent

FundServ CIG6451 (B),CIG6453 (G);CIG6455(H);CIG6456 (I)

Prime Brokers Deutsche Bank, TD Securities

Minimums $25,000 (B,H);$150,000 (G); $500,000 (I)

Management Fee 1.25% (H,I); 1.50% (G); 2.00% (B)

Performance Fee 10% (I); 15% (G), 20% (B,H)

Launch Date March 1, 2012

Subscription Monthly

Redemption Monthly, 45 days notice

Fund Lawrence Park Credit Strategies Fund

Structure Canadian Mutual Fund Trust

Portfolio Managers Andrew Torres, Jason Crowley

Current and prospective investors should note that the Fund utilizes long and short positions in both domestic and international fixed-income products, and may incorporate

leverage and derivative overlays. Fund performance may deviate significantly from benchmark indices shown.

Lawrence Park Capital Partners Ltd. is registered with the Ontario Securities commission as a Portfolio Manager, Investment Fund Manager and Exempt Market

Dealer. The Lawrence Park Credit Strategies Fund is available in Canada to Accredited or Qualified Investors only. Please consult your advisor.

All return figures for the Lawrence Park Credit Strategies Fund (the “Fund” or “LPCSF”) are based on the A Series units and are net of management fees, performance fees,

trailing commissions (if any) and Fund expenses. Other series may have different fees and redemption terms. Monthly returns are based on monthly NAV calculations by RBC

Investor Services.

BGCI refers to the Barclays Global Corporate Index. Returns for this benchmark are calculated as excess monthly returns, or the difference between total returns of the security

and an implied Treasury portfolio matching the term-structure profile of that security. Returns are calculated in Canadian dollars, assuming currency exposures on non-Canadian

holdings are fully hedged. In the opinion of the portfolio managers, this index represents a valid benchmark for the Credit Strategies Fund on the basis it is a) based on a global

portfolio of publically traded corporate bonds, b) expressed in Canadian Dollars, and c) assumes currency and interest rate risk have been hedged from the portfolio.

The XCB is an index-based ETF that replicates the FTSE TMX Canada All Corporate Index, a benchmark index of Canadian Dollar corporate bonds published by PC Bond Analytics.

The Fund has a high % of its assets in C$ corporate bonds, and thus the FTSE TMX Canada All Corporate is a relevant index for comparing risk and return in the Fund. The FTSE

TMX Canada All Corporate Index has a high component of interest rate risk, whereas the Fund has a low component of interest rate risk.

Volatility and Sharpe calculations are based on monthly returns since inception, calculated by the Manager. The risk-free rate used for the Sharpe ratio calculation is 1.00%,

approximately equal to the average Canadian 3 month T-bill rate over the past 12 months. All comparisons to the benchmark are since inception of the Fund, March 1, 2012,

unless noted otherwise.

The Fund’s returns are not guaranteed, its value changes frequently, and past performance may not be repeated. No representations or warranties of any kind are intended or

should be inferred with respect to the economic return or the tax consequences from an investment in the Fund. Potential qualified investors should read the Fund’s offering

memorandum carefully prior to investing.

Ratings and Regional Breakdowns reflect the end of the month portfolio composition on a Total Exposure basis. Total Exposure is equal to the total directional long positions,

plus total directional short positions, excluding hedges & cash. Investors should note that because the portfolio is turned over frequently, current composition may differ

materially from the numbers stated herein.